Chengdu Third People's Hospital, Chengdu Institute of Cardiovascular Diseases, China.
The Fourth People's Hospital of Chengdu, China.
Heart Lung. 2023 May-Jun;59:109-116. doi: 10.1016/j.hrtlng.2023.02.009. Epub 2023 Feb 16.
Many clinical studies have shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular risks, such as heart failure, myocardial infarction and cardiovascular death.
To investigate the use of SGLT2i for the prevention of primary and secondary cardiovascular outcomes.
Pubmed, Embase and Cochrane libraries databases were searched and meta-analysis was performed using Revman 5.4.
Eleven studies with a total of 34,058 cases were analyzed. SGLT2i significantly reduced major adverse cardiovascular events (MACE) in patients with prior myocardial infarction (MI) (OR 0.83, 95% CI 0.73-0.94, p = 0.004), no prior MI (OR 0. 82, 95% CI 0.74-0.90, p<0.0001), prior coronary atherosclerotic disease (CAD) (OR 0.82, 95% CI 0.73-0.93, p = 0.001) and no prior CAD (OR 0.82, 95% CI 0.76-0.91, p = 0.0002) compared with placebo. In addition, SGLT2i significantly reduced hospitalization due to heart failure (HF) in patients with prior MI (OR 0.69, 95% CI 0.55-0.87, p = 0.001), no prior MI (OR 0.63, 95% CI 0.55-0. 72, p<0.00001), prior CAD (OR 0.65, 95% CI 0.53-0.79, p<0.0001) and no prior CAD (OR 0.65, 95% CI 0.56-0.75, p<0.00001) compared with placebo. SGLT2i reduced cardiovascular mortality and all-cause mortality events. MI (OR 0.79, 95% CI 0.70-0.88, p<0.0001), renal damage (OR 0.73, 95% CI 0.58-0.91, p = 0.004), all-cause hospitalization (OR 0.89, 95% CI 0.83-0.96, p = 0.002), systolic and diastolic blood pressure were all significantly reduced in patients receiving SGLT2i.
SGLT2i was effective in prevention of primary and secondary cardiovascular outcomes.
许多临床研究表明，钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）可降低心力衰竭、心肌梗死和心血管死亡等心血管风险。
研究 SGLT2i 预防主要和次要心血管结局的效果。
检索 Pubmed、Embase 和 Cochrane 图书馆数据库，并使用 Revman 5.4 进行荟萃分析。
分析了 11 项共纳入 34058 例患者的研究。SGLT2i 可显著降低有既往心肌梗死（MI）（OR 0.83，95%CI 0.73-0.94，p=0.004）、无既往 MI（OR 0.82，95%CI 0.74-0.90，p<0.0001）、既往冠状动脉粥样硬化性疾病（CAD）（OR 0.82，95%CI 0.73-0.93，p=0.001）和无既往 CAD（OR 0.82，95%CI 0.76-0.91，p=0.0002）患者的主要不良心血管事件（MACE）。此外，SGLT2i 还可显著降低有既往 MI（OR 0.69，95%CI 0.55-0.87，p=0.001）、无既往 MI（OR 0.63，95%CI 0.55-0.72，p<0.00001）、既往 CAD（OR 0.65，95%CI 0.53-0.79，p<0.0001）和无既往 CAD（OR 0.65，95%CI 0.56-0.75，p<0.00001）患者的因心力衰竭（HF）住院率。SGLT2i 可降低心血管死亡率和全因死亡率事件。MI（OR 0.79，95%CI 0.70-0.88，p<0.0001）、肾脏损害（OR 0.73，95%CI 0.58-0.91，p=0.004）、全因住院（OR 0.89，95%CI 0.83-0.96，p=0.002）、收缩压和舒张压均显著降低。
SGLT2i 对预防主要和次要心血管结局有效。
